#USA #New York #Rosen Law Firm #securities lawsuit #Applied Therapeutics

Join the Class Action Against Applied Therapeutics

Investors in Applied Therapeutics, Inc. (NASDAQ: APLT) have an important opportunity to join a class action lawsuit aimed at seeking justice for potential securities violations. The Rosen Law Firm, a recognized authority in investor rights, is leading this initiative and encourages any individuals who purchased APLT securities between January 3, 2024 and December 2, 2024 to get involved. The deadline to serve as a lead plaintiff is set for February 18, 2025.

Understanding the Class Action Process

Initially, it is essential for investors to recognize what being part of a class action entails. Those who bought APLT securities during the specified timeframe may be entitled to compensation without any out-of-pocket costs, thanks to Rosen’s contingency fee arrangement. If you're interested in participating, you may do so by visiting the provided link or contacting Phillip Kim, Esq., who oversees the firm’s outreach regarding this case. A lead plaintiff plays a crucial role in the litigation by representing other investors.

Why Choose the Rosen Law Firm?

The Rosen Law Firm stands out as a reputable choice for investors needing legal representation due to its impressive track record in handling securities class actions and derivative litigation. Historically, the firm has recovered hundreds of millions of dollars for investors. Notably, they achieved the largest settlement against a Chinese company at the time and have consistently ranked among the top securities class action firms since 2013. Notable recognition includes being named number one by ISS Securities Class Action Services for the number of settlements achieved in 2017.

Current Allegations Against Applied Therapeutics

According to the documentation related to the pending lawsuit, there are significant allegations against Applied Therapeutics. It is claimed that assertions made during the class period misled investors, particularly by concealing the company’s adherence to clinical trial protocols and procedures. This concealment created a false sense of security regarding the quality and reliability of clinical data submitted to the FDA for new drug applications. The reality, it seems, was that Applied Therapeutics was not in compliance with good clinical practices, putting the integrity of trial data at substantial risk.

The implications of such misrepresentations, if substantiated, could lead to significant investor losses once the truth came to light. As a result, participating in the class action could be crucial for those impacted by these events.

How to Participate

For investors interested in joining this pressing legal action against Applied Therapeutics, you can find the submission form on the Rosen Law Firm’s website, or call the team directly at 866-767-3653. It's vital to note that while you can participate in the class action process without an attorney, selecting qualified legal counsel is recommended to navigate the complexities of the case efficiently.

It is important to remember that no class has been certified yet — until further developments occur, investors are not officially represented unless they choose to retain counsel.

Follow-Up and Updates

For the latest information, including updates on this case, investors are encouraged to follow the Rosen Law Firm on their LinkedIn, Twitter, or Facebook social media platforms. As developments unfold, keeping abreast of new announcements can prove beneficial for affected investors.

In conclusion, for those who have invested in Applied Therapeutics during the specified period, this is a critical moment to act. By joining this class action lawsuit, you not only stand to recover potential losses incurred, but also contribute to accountability in corporate governance within the health sector.

Don’t hesitate: make your voice heard today. Secure your rights as investors and ensure your financial interests are protected under the guidance of esteemed legal experts.

• ---